UK-based Ziarco Pharma Ltd. recently announced positive phase 2a results for ZPL-389, a once daily oral histamine H4 receptor antagonist, for the treatment of moderate to severe atopic dermatitis.
Atopic Dermatitis
Latest News
Advertisement
Advertisement
The systemic therapy dupilumab met primary endpoints in two phase 3 studies on adults with in inadequately controlled moderate-to-severe atopic dermatitis.
Pfizer and Anacor Pharmaceuticals announced in May that the pharmaceutical companies merged with Pfizer acquiring Anacor for about $5.2 billion. Dermatologists say merger is a good move for patients.
Good for more than a morning meal, oatmeal soothes angry skin, relieves itching, and even has an antimicrobial effect.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
Dr. Charrow Highlights Earlier Biologic Use and Deroofing in Hidradenitis Suppurativa
3
From Mechanism to Management: Navigating Male Pattern Hair Loss and New Topical Therapies
4
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
5